SUN-335 Abaloparatide Prevents Unloading-Induced Bone Loss in Adult Rats

Teguh D, Nustad J, Craven A, Brooks D, Arlt H, Lanske B, Bouxsein M

Journal of the Endocrine Society8 May 2020

PMCIDPMC7207745PepBankPUB-99001617

Read at source Source pageAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study11

10 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats, serum TRAcP5b did not differ among groups including both abaloparatide groups.
In plain wordsIn rats, serum TRAcP5b did not differ among groups including both abaloparatide groups.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeSerum TRAcP5b
Study
ratn = 40
adult male Wistar rats
Comparator
all study groups
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25µg/kg/day · subcutaneous · 28 daysAs given in this study (rat).
Source sentences
Summary
Serum TRAcP5b did not differ among groups, yet both ABL groups had higher OCN levels than the VEH-treated control groups (+63%, p<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Adult male Wistar rats, 13–14 weeks of age, were assigned to 1 of 4 groups (10 rats/group): ambulatory + vehicle (CON-VEH), ambulatory + ABL (CON-ABL), HLU + vehicle (HLU-VEH) or HLU + ABL (HLU-ABL).
Summary · context
The rats received a daily subcutaneous injection of ABL (25µg/kg/day) or vehicle for 28 days.
Report a problemFND-9900161710
02AnimalAnimal study (in vivo)Efficacy outcome
In rats, both abaloparatide groups had higher osteocalcin levels than vehicle-treated control groups.
In plain wordsIn rats, both abaloparatide groups had higher osteocalcin levels than vehicle-treated control groups.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseSerum osteocalcin
Study
ratn = 40
adult male Wistar rats
Comparator
vehicle-treated control groups
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25µg/kg/day · subcutaneous · 28 daysAs given in this study (rat).
Measurements
Osteocalcin difference
63%
abaloparatide groups versus vehicle controls
Source sentences
Summary
Serum TRAcP5b did not differ among groups, yet both ABL groups had higher OCN levels than the VEH-treated control groups (+63%, p<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Adult male Wistar rats, 13–14 weeks of age, were assigned to 1 of 4 groups (10 rats/group): ambulatory + vehicle (CON-VEH), ambulatory + ABL (CON-ABL), HLU + vehicle (HLU-VEH) or HLU + ABL (HLU-ABL).
Summary · context
The rats received a daily subcutaneous injection of ABL (25µg/kg/day) or vehicle for 28 days.
Report a problemFND-9900161711
03AnimalAnimal study (in vivo)Efficacy outcome
In ambulatory rats, abaloparatide increased total vBMD more than vehicle.
In plain wordsIn ambulatory rats, abaloparatide increased total bone density more than vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTotal vBMD in ambulatory rats
Study
ratn = 20
adult male Wistar rats
Comparator
ambulatory vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25µg/kg/day · subcutaneous · 28 daysAs given in this study (rat).
Measurements
Total vBMD change
52%
ABL-CON
Total vBMD change
20%
VEH-CON
Source sentences
Summary
Longitudinal pQCT revealed significant increases in total vBMD in ABL-CON (52±17%) vs. VEH-CON (20±5%); and in HLU-ABL (24±6%) vs. HLU-VEH (-2±3%) (p<0.001 for both).
2 context sentences(design, population, supporting numbers)
Summary · context
Adult male Wistar rats, 13–14 weeks of age, were assigned to 1 of 4 groups (10 rats/group): ambulatory + vehicle (CON-VEH), ambulatory + ABL (CON-ABL), HLU + vehicle (HLU-VEH) or HLU + ABL (HLU-ABL).
Summary · context
The rats received a daily subcutaneous injection of ABL (25µg/kg/day) or vehicle for 28 days.
Report a problemFND-9900161701
04AnimalAnimal study (in vivo)Efficacy outcome
In unloaded rats, abaloparatide increased total vBMD compared with vehicle.
In plain wordsIn unloaded rats, abaloparatide increased total bone density compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTotal vBMD in unloaded rats
Study
ratn = 20
adult male Wistar rats
Comparator
HLU vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25µg/kg/day · subcutaneous · 28 daysAs given in this study (rat).
Measurements
Total vBMD change
24%
HLU-ABL
Total vBMD change
−2%
HLU-VEH
Source sentences
Summary
Longitudinal pQCT revealed significant increases in total vBMD in ABL-CON (52±17%) vs. VEH-CON (20±5%); and in HLU-ABL (24±6%) vs. HLU-VEH (-2±3%) (p<0.001 for both).
2 context sentences(design, population, supporting numbers)
Summary · context
Adult male Wistar rats, 13–14 weeks of age, were assigned to 1 of 4 groups (10 rats/group): ambulatory + vehicle (CON-VEH), ambulatory + ABL (CON-ABL), HLU + vehicle (HLU-VEH) or HLU + ABL (HLU-ABL).
Summary · context
The rats received a daily subcutaneous injection of ABL (25µg/kg/day) or vehicle for 28 days.
Report a problemFND-9900161702
05AnimalAnimal study (in vivo)Efficacy outcome
In unloaded rats, abaloparatide increased distal femur trabecular bone volume fraction versus vehicle.
In plain wordsIn unloaded rats, abaloparatide increased distal femur trabecular bone volume fraction compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseDistal femur trabecular bone volume fraction
Study
ratn = 20
adult male Wistar rats
Comparator
HLU vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25µg/kg/day · subcutaneous · 28 daysAs given in this study (rat).
Measurements
Bone volume fraction difference
66.5%
HLU-ABL versus HLU-VEH
Source sentences
Summary
ABL prevented these negative effects, such that Tb.BV/TV, thickness and BMD were 66.5%, 39% and 50.3% higher in HLU-ABL compared to HLU-VEH (p<0.01 for all).
3 context sentences(design, population, supporting numbers)
Summary · context
Significant differences were observed in the µCT analysis of the distal femur: Tb.BV/TV, thickness and BMD were 43.7%, 12.9% and 27.4% lower, respectively, in HLU-VEH compared to CON-VEH (p<0.05 for all).
Summary · context
Adult male Wistar rats, 13–14 weeks of age, were assigned to 1 of 4 groups (10 rats/group): ambulatory + vehicle (CON-VEH), ambulatory + ABL (CON-ABL), HLU + vehicle (HLU-VEH) or HLU + ABL (HLU-ABL).
Summary · context
The rats received a daily subcutaneous injection of ABL (25µg/kg/day) or vehicle for 28 days.
Report a problemFND-9900161703
06AnimalAnimal study (in vivo)Efficacy outcome
In unloaded rats, abaloparatide increased distal femur trabecular thickness versus vehicle.
In plain wordsIn unloaded rats, abaloparatide increased distal femur trabecular thickness compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseDistal femur trabecular thickness
Study
ratn = 20
adult male Wistar rats
Comparator
HLU vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25µg/kg/day · subcutaneous · 28 daysAs given in this study (rat).
Measurements
Trabecular thickness difference
39%
HLU-ABL versus HLU-VEH
Source sentences
Summary
ABL prevented these negative effects, such that Tb.BV/TV, thickness and BMD were 66.5%, 39% and 50.3% higher in HLU-ABL compared to HLU-VEH (p<0.01 for all).
3 context sentences(design, population, supporting numbers)
Summary · context
Significant differences were observed in the µCT analysis of the distal femur: Tb.BV/TV, thickness and BMD were 43.7%, 12.9% and 27.4% lower, respectively, in HLU-VEH compared to CON-VEH (p<0.05 for all).
Summary · context
Adult male Wistar rats, 13–14 weeks of age, were assigned to 1 of 4 groups (10 rats/group): ambulatory + vehicle (CON-VEH), ambulatory + ABL (CON-ABL), HLU + vehicle (HLU-VEH) or HLU + ABL (HLU-ABL).
Summary · context
The rats received a daily subcutaneous injection of ABL (25µg/kg/day) or vehicle for 28 days.
Report a problemFND-9900161704
07AnimalAnimal study (in vivo)Efficacy outcome
In unloaded rats, abaloparatide increased distal femur trabecular BMD versus vehicle.
In plain wordsIn unloaded rats, abaloparatide increased distal femur trabecular bone density compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseDistal femur trabecular BMD
Study
ratn = 20
adult male Wistar rats
Comparator
HLU vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25µg/kg/day · subcutaneous · 28 daysAs given in this study (rat).
Measurements
Trabecular BMD difference
50.3%
HLU-ABL versus HLU-VEH
Source sentences
Summary
ABL prevented these negative effects, such that Tb.BV/TV, thickness and BMD were 66.5%, 39% and 50.3% higher in HLU-ABL compared to HLU-VEH (p<0.01 for all).
3 context sentences(design, population, supporting numbers)
Summary · context
Significant differences were observed in the µCT analysis of the distal femur: Tb.BV/TV, thickness and BMD were 43.7%, 12.9% and 27.4% lower, respectively, in HLU-VEH compared to CON-VEH (p<0.05 for all).
Summary · context
Adult male Wistar rats, 13–14 weeks of age, were assigned to 1 of 4 groups (10 rats/group): ambulatory + vehicle (CON-VEH), ambulatory + ABL (CON-ABL), HLU + vehicle (HLU-VEH) or HLU + ABL (HLU-ABL).
Summary · context
The rats received a daily subcutaneous injection of ABL (25µg/kg/day) or vehicle for 28 days.
Report a problemFND-9900161705
08AnimalAnimal study (in vivo)Efficacy outcome
In ambulatory rats, abaloparatide increased femoral stiffness versus vehicle.
In plain wordsIn ambulatory rats, abaloparatide increased femoral stiffness compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFemoral stiffness
Study
ratn = 20
adult male Wistar rats
Comparator
ambulatory vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25µg/kg/day · subcutaneous · 28 daysAs given in this study (rat).
Measurements
Femoral stiffness difference
22.9%
CON-ABL versus CON-VEH
Source sentences
Summary
CON-ABL had greater femoral stiffness (+22.9%, p=0.03) and ultimate load (+20.5%, p=0.01) than CON-VEH.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult male Wistar rats, 13–14 weeks of age, were assigned to 1 of 4 groups (10 rats/group): ambulatory + vehicle (CON-VEH), ambulatory + ABL (CON-ABL), HLU + vehicle (HLU-VEH) or HLU + ABL (HLU-ABL).
Summary · context
The rats received a daily subcutaneous injection of ABL (25µg/kg/day) or vehicle for 28 days.
Report a problemFND-9900161707
09AnimalAnimal study (in vivo)Efficacy outcome
In ambulatory rats, abaloparatide increased femoral ultimate load versus vehicle.
In plain wordsIn ambulatory rats, abaloparatide increased the load needed to break the femur compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFemoral ultimate load
Study
ratn = 20
adult male Wistar rats
Comparator
ambulatory vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25µg/kg/day · subcutaneous · 28 daysAs given in this study (rat).
Measurements
Ultimate load difference
20.5%
CON-ABL versus CON-VEH
Source sentences
Summary
CON-ABL had greater femoral stiffness (+22.9%, p=0.03) and ultimate load (+20.5%, p=0.01) than CON-VEH.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult male Wistar rats, 13–14 weeks of age, were assigned to 1 of 4 groups (10 rats/group): ambulatory + vehicle (CON-VEH), ambulatory + ABL (CON-ABL), HLU + vehicle (HLU-VEH) or HLU + ABL (HLU-ABL).
Summary · context
The rats received a daily subcutaneous injection of ABL (25µg/kg/day) or vehicle for 28 days.
Report a problemFND-9900161708
10AnimalAnimal study (in vivo)Efficacy outcome
In rats, vertebral and tibial trabecular parameters followed the distal femur pattern under abaloparatide treatment.
In plain wordsIn rats, vertebral and tibial trabecular results followed the distal femur pattern with abaloparatide compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseVertebral and tibial trabecular parameters
Study
ratn: not reported in source
adult male Wistar rats
Comparator
vehicle-treated groups
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25µg/kg/day · subcutaneous · 28 daysAs given in this study (rat).
Source sentences
Summary
Vertebral and tibial trabecular parameters mimicked the distal femur parameters.
3 context sentences(design, population, supporting numbers)
Summary · context
ABL prevented these negative effects, such that Tb.BV/TV, thickness and BMD were 66.5%, 39% and 50.3% higher in HLU-ABL compared to HLU-VEH (p<0.01 for all).
Summary · context
Adult male Wistar rats, 13–14 weeks of age, were assigned to 1 of 4 groups (10 rats/group): ambulatory + vehicle (CON-VEH), ambulatory + ABL (CON-ABL), HLU + vehicle (HLU-VEH) or HLU + ABL (HLU-ABL).
Summary · context
The rats received a daily subcutaneous injection of ABL (25µg/kg/day) or vehicle for 28 days.
Report a problemFND-9900161709

Studies that did not test the peptide alone1

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

11AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome
In rats, the abstract describes a positive abaloparatide morphology effect in CON-VEH rats, leaving the treatment contrast unclear.
In plain wordsIn rats, the abstract describes a positive abaloparatide effect in a vehicle group, leaving the treatment comparison unclear.
Peptide
Abaloparatide (Tymlos)
Outcome
Direction not reportedBone morphology in ambulatory rats
Study
ratn: not reported in source
adult male Wistar rats
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
A positive impact of ABL on bone morphology was also seen in the CON-VEH rats.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult male Wistar rats, 13–14 weeks of age, were assigned to 1 of 4 groups (10 rats/group): ambulatory + vehicle (CON-VEH), ambulatory + ABL (CON-ABL), HLU + vehicle (HLU-VEH) or HLU + ABL (HLU-ABL).
Summary · context
The rats received a daily subcutaneous injection of ABL (25µg/kg/day) or vehicle for 28 days.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-9900161706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Abstract

PepBank is a research reference. Talk to a doctor before you use any peptide.